Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov 6;7(4):96.
doi: 10.3390/antibiotics7040096.

First Description of Colistin and Tigecycline-Resistant Acinetobacter baumannii Producing KPC-3 Carbapenemase in Portugal

Cátia Caneiras  1   2 , Filipa Calisto  3   4 , Gabriela Jorge da Silva  5 , Luis Lito  6 , José Melo-Cristino  7   8 , Aida Duarte  9
Affiliations
Case Reports

First Description of Colistin and Tigecycline-Resistant Acinetobacter baumannii Producing KPC-3 Carbapenemase in Portugal

Cátia Caneiras et al. Antibiotics (Basel). .

Abstract

Herein, we describe a case report of carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae isolates that were identified from the same patient at a Tertiary University Hospital Centre in Portugal. Antimicrobial susceptibility and the molecular characterization of resistance and virulence determinants were performed. PCR screening identified the presence of the resistance genes blaKPC-3, blaTEM-1 and blaSHV-1 in both isolates. The KPC-3 K. pneumoniae isolate belonged to the ST-14 high risk clone and accumulated an uncommon resistance and virulence profile additional to a horizontal dissemination capacity. In conclusion, the molecular screening led to the first identification of the A. baumannii KPC-3 producer in Portugal with a full antimicrobial resistance profile including tigecycline and colistin.

Keywords: A. baumannii; Gram-negative bacteria; K. pneumoniae; KPC-3 carbapenemase; antimicrobial resistance; colistin; tigecycline.

PubMed Disclaimer

Conflict of interest statement

J.M.-C. received research grants administered through his university and honoraria for serving on the speaker’s bureaus of Pfizer, Gilead and Novartis. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Butler C.C. Antibiotics: Responding to a Global Challenge. Antibiotics. 2012;1:14–16. doi: 10.3390/antibiotics1010014. - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control . Antimicrobial Resistance Surveillance in Europe 2014. European Centre for Disease Prevention and Control; Stockholm, Sweden: 2015.
    1. Perez F., Bonomo R.A. Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. Lancet Infect. Dis. 2018;18:358–360. doi: 10.1016/S1473-3099(18)30112-9. - DOI - PubMed
    1. Tacconelli E., Magrini N. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. World Health Organization; Geneva, Switzerland: 2017.
    1. Beceiro A., Tomas M., Bou G. Antimicrobial resistance and virulence: A successful or deleterious association in the bacterial world? Clin. Microbiol. Rev. 2013;26:185–230. doi: 10.1128/CMR.00059-12. - DOI - PMC - PubMed

Publication types

LinkOut - more resources